Cresset Asset Management
PVLA icon

Cresset Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Cresset Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
11,629
-231
-2% -$28K 0.01% 705
2026
Q1 		$1.48M Buy
11,860
+431
+4% +$45K 0.01% 645
2025
Q4 		$1.2M Sell
11,429
-5,995
-34% -$511K 0.01% 733
2025
Q3 		$1.09M Sell
17,424
-3,487
-17% -$155K ﹤0.01% 712
2025
Q2 		$471K Hold
20,911
– – ﹤0.01% 956
2025
Q1 		$585K Hold
20,911
– – ﹤0.01% 993
2024
Q4 		$251K Buy
+20,911
New +$328K ﹤0.01% 1441

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Cresset Asset Management's PVLA Position: Q2 2026 in Review

Cresset Asset Management reduced its Palvella Therapeutics (PVLA) stake by 1.9% in Q2 2026, selling an estimated $28K and leaving 11,629 shares worth $1.78M. The position accounts for 0.01% of the portfolio, ranked #705.

Cresset Asset Management first reported a position in PVLA in Q4 2024 and has held it in 7 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Cresset Asset Management held 11,629 shares of Palvella Therapeutics worth $1.78M as of Q2 2026.
  • Cresset Asset Management sold 231 Palvella Therapeutics shares in Q2 2026, an estimated $28K.
  • Palvella Therapeutics made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #705 holding.
  • Cresset Asset Management first reported a position in Palvella Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.